146 related articles for article (PubMed ID: 34055604)
1. The Application of and Factors Influencing, the NB5 Assay in Neuroblastomas.
Wang Z; Wang C; Xu Y; Le J; Jiang Y; Yao W; Wang H; Li K
Front Oncol; 2021; 11():633106. PubMed ID: 34055604
[TBL] [Abstract][Full Text] [Related]
2. RT-PCR demonstrates superior sensitivity and specificity in detecting the five neuroblastoma genes compared to the flow cytometry method for measurable residual disease.
Tian X; Li H; Luo T; Mao J; Yuan X; Gao Q; Xiao J; Qian S; Zou R; Chen K; Zhu C; Yi C; He X
Transl Pediatr; 2023 Dec; 12(12):2232-2246. PubMed ID: 38197110
[TBL] [Abstract][Full Text] [Related]
3. Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.
Asgharzadeh S; Marachelian A; Villablanca JG; Liu WY; Kennedy R; Sposto R; Naranjo A; Tenney S; Yu AL; Ozkaynak MF; Sondel PM; Park JR; Seeger RC
Pediatr Blood Cancer; 2022 Sep; 69(9):e29719. PubMed ID: 35441784
[TBL] [Abstract][Full Text] [Related]
4. Distinct Expression Profiles of Neuroblastoma-Associated mRNAs in Peripheral Blood and Bone Marrow of Non-High-Risk and High-Risk Neuroblastoma Patients.
Nakatani N; Win KHN; Mon CY; Fujikawa T; Uemura S; Saito A; Ishida T; Mori T; Hasegawa D; Kosaka Y; Inoue S; Nishimura A; Nino N; Tamura A; Yamamoto N; Nozu K; Nishimura N
Biology (Basel); 2024 May; 13(5):. PubMed ID: 38785826
[TBL] [Abstract][Full Text] [Related]
5. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Yalcin B; Dee R; van Noesel MM; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
Clin Chem; 2009 Jul; 55(7):1316-26. PubMed ID: 19460840
[TBL] [Abstract][Full Text] [Related]
6. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA.
Miyajima Y; Kato K; Numata S; Kudo K; Horibe K
Cancer; 1995 Jun; 75(11):2757-61. PubMed ID: 7743482
[TBL] [Abstract][Full Text] [Related]
7. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
8. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.
Marachelian A; Villablanca JG; Liu CW; Liu B; Goodarzian F; Lai HA; Shimada H; Tran HC; Parra JA; Gallego R; Bedrossian N; Young S; Czarnecki S; Kennedy R; Weiss BD; Goldsmith K; Granger M; Matthay KK; Groshen S; Asgharzadeh S; Sposto R; Seeger RC
Clin Cancer Res; 2017 Sep; 23(18):5374-5383. PubMed ID: 28559462
[No Abstract] [Full Text] [Related]
9. Minimal Residual Disease Detected by the 7NB-mRNAs ddPCR Assay Is Associated with Disease Progression in High-Risk Neuroblastoma Patients: A Prospective Multicenter Observational Study in Japan.
Nishimura N; Ishida T; Yokota I; Matsumoto K; Shichino H; Fujisaki H; Sarashina T; Kamijo T; Takimoto T; Iehara T; Tajiri T; On Behalf Of The Jccg Neuroblastoma Committee
Biology (Basel); 2023 Oct; 12(10):. PubMed ID: 37887060
[TBL] [Abstract][Full Text] [Related]
10. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma.
Komada Y; Zhang XL; Zhou YW; Inaba H; Deguchi T; Azuma E; Sakurai M
Cancer; 1998 Feb; 82(3):591-9. PubMed ID: 9452279
[TBL] [Abstract][Full Text] [Related]
12. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma.
Cheung IY; Cheung NK
Clin Cancer Res; 1997 May; 3(5):821-6. PubMed ID: 9815755
[TBL] [Abstract][Full Text] [Related]
13. The expression of PHOX2B in bone marrow and peripheral blood predicts adverse clinical outcome in non-high-risk neuroblastoma.
Fan H; Xing T; Hong H; Duan C; Zhao W; Zhao Q; Wang X; Huang C; Zhu S; Jin M; Su Y; Gao C; Ma X
Pediatr Hematol Oncol; 2022 May; 39(4):343-356. PubMed ID: 34752187
[TBL] [Abstract][Full Text] [Related]
14. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
Cheung IY; Sahota A; Cheung NK
Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.
Yamamoto N; Kozaki A; Hartomo TB; Yanai T; Hasegawa D; Kawasaki K; Kosaka Y; Matsuo M; Hirase S; Mori T; Hayakawa A; Iijima K; Nishio H; Nishimura N
Oncol Lett; 2015 Nov; 10(5):3228-3232. PubMed ID: 26722317
[TBL] [Abstract][Full Text] [Related]
16. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
[TBL] [Abstract][Full Text] [Related]
17. Reverse transcriptase/polymerase chain reaction analysis of parathyroid hormone-related protein for the detection of tumor cell dissemination in the peripheral blood and bone marrow of patients with breast cancer.
Wulf GG; Jürgens B; Liersch T; Gatzemeier W; Rauschecker H; Buske C; Hüfner M; Hiddemann W; Wörmann B
J Cancer Res Clin Oncol; 1997; 123(9):514-21. PubMed ID: 9341902
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood.
Lin KS; Uemura S; Thwin KKM; Nakatani N; Ishida T; Yamamoto N; Tamura A; Saito A; Mori T; Hasegawa D; Kosaka Y; Nino N; Nagano C; Takafuji S; Iijima K; Nishimura N
Transl Oncol; 2021 Aug; 14(8):101019. PubMed ID: 33993097
[TBL] [Abstract][Full Text] [Related]
19. Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high‑risk neuroblastoma: A case report.
Inoue S; Win KHN; Mon CY; Fujikawa T; Hyodo S; Uemura S; Ishida T; Mori T; Hasegawa D; Kosaka Y; Nishimura A; Nakatani N; Nino N; Tamura A; Yamamoto N; Nozu K; Nishimura N
Oncol Lett; 2023 Sep; 26(3):369. PubMed ID: 37559575
[TBL] [Abstract][Full Text] [Related]
20. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.
Yáñez Y; Grau E; Oltra S; Cañete A; Martínez F; Orellana C; Noguera R; Palanca S; Castel V
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1263-72. PubMed ID: 21706131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
